VEZF1: A Potential Drug Target and Biomarker for Vascular Disease

Target Name: VEZF1

NCBI ID: G7716

VEZF1

VEZF1: A Potential Drug Target and Biomarker for Vascular Disease

Vascular disease is a leading cause of morbidity and mortality worldwide, accounting for approximately 17% of the global mortality. The consequences of vascular disease include a wide range of physiological and pathological changes, including increased risk of cardiovascular events, stroke, and neurodegeneration. Given the significant impact of vascular disease, there is a urgent need for new therapeutic approaches to treat these conditions.

VEZF1, a gene that encodes for a zinc finger protein, has been identified as a potential drug target and biomarker for vascular disease. In this article, we will explore the biology of VEZF1 and its potential as a drug target.

The biology of VEZF1

VEZF1 is a member of the ZNF family, which includes a variety of zinc finger proteins that regulate gene expression and cell function. These proteins are characterized by the presence of a zinc finger domain, which consists of a series of amino acids that are highly conserved and often include a positive charge. The zinc finger domain is responsible for the protein's unique structure and function.

VEZF1 is expressed in a variety of tissues and cells, including blood vessels, immune cells, and epithelial cells. It is highly expressed in endothelial cells, which are the cells that line the blood vessels and play a crucial role in maintaining blood flow. This is why VEZF1 has been identified as a potential drug target for vascular disease.

VEZF1 functions as a negative regulator of angiogenesis, which is the process by which new blood vessels are formed. Angiogenesis is a critical process for maintaining blood flow and oxygenation, but it can also contribute to the development of vascular disease. VEZF1 plays a negative role in angiogenesis by regulating the growth and proliferation of endothelial cells.

In addition to its role in angiogenesis, VEZF1 has also been shown to participate in the regulation of cellular processes that are important for maintaining blood vessel function. For example, VEZF1 has been shown to regulate the formation of blood-brain barrier (BBB), which is a barrier that separates the brain from the bloodstream. The BBB is critical for maintaining the integrity of the blood-brain barrier and protecting the brain from harmful substances.

VEZF1 as a drug target

VEZF1's unique biology and function make it an attractive target for drug development. Several studies have shown that VEZF1 can be modulated by small molecules, making it a potential drug target.

One of the most promising strategies for modulating VEZF1 is the use of small molecules that can bind to specific amino acid residues within the zinc finger domain. These small molecules can modulate the activity of VEZF1 and potentially inhibit its negative regulation of angiogenesis.

VEZF1 has been shown to be sensitive to several small molecules, including inhibitors of angiogenesis, such as the drug NG4012, which is a inhibitor of the smooth muscle-derived angiogenesis factor (SMAD). NG4012 has been shown to inhibit the activity of VEZF1 and reduce the formation of blood vessels in animal models of angiogenesis.

Another potential drug target for VEZF1 is the use of small molecules that can modulate the activity of VEZF1's negative regulator, the transcription factor, PIK3CA. PIK3CA is a key regulator of angiogenesis and has been shown to be involved in the regulation of VEZF1.

In addition to its potential as a drug target, VEZF1 is also a potential biomarker for

Protein Name: Vascular Endothelial Zinc Finger 1

Functions: Possible transcription factor. Specifically binds to the CT/GC-rich region of the interleukin-3 promoter and mediates tax transactivation of IL-3

The "VEZF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VEZF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets